{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:24:22Z","timestamp":1787628262366,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biophysical Journal"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bpj.2022.05.030","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:02:21Z","timestamp":1653994941000},"page":"2251-2265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"121","author":[{"given":"Yonglan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunbum","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-9928","authenticated-orcid":false,"given":"Chung-Jung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Nussinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpj.2022.05.030_bib1","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib2","doi-asserted-by":"crossref","first-page":"17268","DOI":"10.1002\/ange.202105383","article-title":"Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL inhibitors\u2217","volume":"133","author":"Quach","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bpj.2022.05.030_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bpj.2022.05.030_bib4","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bpj.2022.05.030_bib5","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1021\/acs.jctc.9b00119","article-title":"Atomistic modeling of the ABL kinase regulation by allosteric modulators using structural perturbation analysis and community-based network reconstruction of allosteric communications","volume":"15","author":"Astl","year":"2019","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.bpj.2022.05.030_bib6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bpj.2022.05.030_bib7","doi-asserted-by":"crossref","first-page":"43662","DOI":"10.18632\/oncotarget.18216","article-title":"Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.bpj.2022.05.030_bib8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","article-title":"Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)","volume":"100","author":"Mian","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bpj.2022.05.030_bib9","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cells9112435","article-title":"Targeting the interaction between the SH3 domain of Grb2 and Gab2","volume":"9","author":"Malagrin\u00f2","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bpj.2022.05.030_bib10","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway","volume":"23","author":"Naughton","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bpj.2022.05.030_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111451118","article-title":"Mutation in Abl kinase\u00a0with altered drug-binding kinetics indicates a novel mechanism of\u00a0imatinib resistance","volume":"118","author":"Lyczek","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.bpj.2022.05.030_bib12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V96.2.664","article-title":"The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr\/Abl tyrosine kinase","volume":"96","author":"Million","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bpj.2022.05.030_bib13","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00018-019-03397-7","article-title":"Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex","volume":"77","author":"Gregor","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bpj.2022.05.030_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: bcr-abl","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/leu.2013.323","article-title":"Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist","volume":"28","author":"Zhang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bpj.2022.05.030_bib16","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bpj.2022.05.030_bib17","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bpj.2022.05.030_bib18","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.92.24.10889","article-title":"Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation","volume":"92","author":"Gishizky","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.bpj.2022.05.030_bib19","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/blood.V98.6.1773","article-title":"Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes","volume":"98","author":"Kardinal","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bpj.2022.05.030_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Modi","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bpj.2022.05.030_bib21","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","article-title":"BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia","volume":"67","author":"Chu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib22","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","article-title":"The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr\/abl","volume":"99","author":"He","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bpj.2022.05.030_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/MCB.21.3.840-853.2001","article-title":"The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl","volume":"21","author":"Zhang","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib24","doi-asserted-by":"crossref","first-page":"104082","DOI":"10.1016\/j.dib.2019.104082","article-title":"Outlining the Grb2 interactome data and its interacting partners in HEK293 cells in absence and presence of epidermal growth factor","volume":"25","author":"Duggal","year":"2019","journal-title":"Data Brief"},{"key":"10.1016\/j.bpj.2022.05.030_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12964-019-0451-2","article-title":"The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-Grb2-and time-dependent manner","volume":"17","author":"Bongartz","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bpj.2022.05.030_bib26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s42003-021-02149-3","article-title":"Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line","volume":"4","author":"Pudewell","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib27","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1042\/BCJ20210105","article-title":"The intramolecular allostery of GRB2 governing its interaction with SOS1 is modulated by phosphotyrosine ligands","volume":"478","author":"Kazemein Jasemi","year":"2021","journal-title":"Biochem.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1107\/S2053230X20007232","article-title":"Crystal structure of the SH3 domain of growth factor receptor-bound protein 2","volume":"76","author":"Bolgov","year":"2020","journal-title":"Acta. Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.bpj.2022.05.030_bib29","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1038\/s41598-021-85578-8","article-title":"Composition of receptor tyrosine kinase-mediated lipid micro-domains controlled by adaptor protein interaction","volume":"11","author":"Rohwedder","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bpj.2022.05.030_bib30","doi-asserted-by":"crossref","first-page":"7354","DOI":"10.1038\/ncomms8354","article-title":"Grb2 monomer\u2013dimer equilibrium determines normal versus oncogenic function","volume":"6","author":"Ahmed","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bpj.2022.05.030_bib31","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/0008-5472.CAN-19-4031","article-title":"Epigenetic and posttranscriptional modulation of SOS1 can promote breast cancer metastasis through obesity-activated c-met signaling in african-American women","volume":"81","author":"Xing","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2020.11960","article-title":"GRB2-associated binding protein 2 regulates multiple pathways associated with the development of prostate cancer","volume":"20","author":"Qiao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bpj.2022.05.030_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.cad.0000185180.72604.ac","article-title":"Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy","volume":"17","author":"Dharmawardana","year":"2006","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.bpj.2022.05.030_bib34","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1073\/pnas.142224499","article-title":"Specificity and affinity motifs for Grb2 SH2-ligand interactions","volume":"99","author":"Kessels","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.bpj.2022.05.030_bib35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/j.1460-2075.1993.tb05842.x","article-title":"The SH2\/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling","volume":"12","author":"Skolnik","year":"1993","journal-title":"EMBO\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1006\/jmbi.1998.1790","article-title":"Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands","volume":"279","author":"Rahuel","year":"1998","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib37","doi-asserted-by":"crossref","first-page":"e1000487","DOI":"10.1371\/journal.pcbi.1000487","article-title":"Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations","volume":"5","author":"Dixit","year":"2009","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nsb0796-586","article-title":"Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode","volume":"3","author":"Rahuel","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s42003-021-01969-7","article-title":"Grb2 binding induces phosphorylation-independent activation of Shp2","volume":"4","author":"Lin","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib40","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1021\/jacs.9b10710","article-title":"High-affinity interactions of the nSH3\/cSH3 domains of Grb2 with the C-terminal proline-rich domain of SOS1","volume":"142","author":"Liao","year":"2020","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.bpj.2022.05.030_bib41","doi-asserted-by":"crossref","first-page":"128354","DOI":"10.1016\/j.bmcl.2021.128354","article-title":"Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain","volume":"51","author":"Xiao","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.bpj.2022.05.030_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s12551-018-0461-0","article-title":"Autoinhibition in Ras effectors Raf, PI3K\u03b1, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention","volume":"10","author":"Nussinov","year":"2018","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.bpj.2022.05.030_bib43","doi-asserted-by":"crossref","first-page":"eaax2364","DOI":"10.1126\/scisignal.aax2364","article-title":"Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis","volume":"13","author":"Kharbanda","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bpj.2022.05.030_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib45","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib46","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1039\/D0SC01676D","article-title":"PI3K inhibitors: review and new strategies","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bpj.2022.05.030_bib47","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.febslet.2012.04.054","article-title":"The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction","volume":"586","author":"Liu","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bpj.2022.05.030_bib48","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib49","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.str.2021.02.005","article-title":"B-Raf autoinhibition in the presence and absence of 14-3-3","volume":"29","author":"Zhang","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.bpj.2022.05.030_bib50","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1016\/j.csbj.2021.06.007","article-title":"The mechanism of activation of monomeric B-Raf V600E","volume":"19","author":"Maloney","year":"2021","journal-title":"Comput. Struct. Biotechnol.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib51","first-page":"341a","article-title":"The mechanism of PI3K\u03b1 activation at the atomic level","volume":"116","author":"Zhang","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bpj.2022.05.030_bib52","doi-asserted-by":"crossref","first-page":"102438","DOI":"10.1016\/j.isci.2021.102438","article-title":"The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane","volume":"24","author":"Jang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.bpj.2022.05.030_bib53","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bpj.2022.05.030_bib55","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1021\/jp101759q","article-title":"Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types","volume":"114","author":"Klauda","year":"2010","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.bpj.2022.05.030_bib56","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.181342398","article-title":"Electrostatics of nanosystems: application to microtubules and the ribosome","volume":"98","author":"Baker","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.bpj.2022.05.030_bib57","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera - a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib58","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.bpj.2021.03.018","article-title":"The structural basis of Akt PH domain interaction with calmodulin","volume":"120","author":"Weako","year":"2021","journal-title":"Biophys.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib59","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.str.2019.08.009","article-title":"The structural basis of the farnesylated and methylated KRas4B interaction with calmodulin","volume":"27","author":"Jang","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.bpj.2022.05.030_bib60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bpj.2018.07.016","article-title":"Allosteric KRas4B can modulate SOS1 fast and slow Ras activation cycles","volume":"115","author":"Liao","year":"2018","journal-title":"Biophys.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib61","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1074\/jbc.RA117.001596","article-title":"Unraveling the molecular mechanism of interactions of the Rho GTPases Cdc42 and Rac1 with the scaffolding protein IQGAP2","volume":"293","author":"Ozdemir","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib62","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1074\/jbc.M117.785063","article-title":"Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction","volume":"292","author":"Jang","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib63","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.bpj.2017.09.008","article-title":"Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains","volume":"113","author":"Zhang","year":"2017","journal-title":"Biophys.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib64","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1042\/BCJ20160031","article-title":"Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers","volume":"473","author":"Jang","year":"2016","journal-title":"Biochem.\u00a0J."},{"key":"10.1016\/j.bpj.2022.05.030_bib65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/jcc.10321","article-title":"Generalized born model with a simple smoothing function","volume":"24","author":"Im","year":"2003","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.bpj.2022.05.030_bib66","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.molcel.2006.06.001","article-title":"The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling","volume":"22","author":"Liu","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bpj.2022.05.030_bib67","doi-asserted-by":"crossref","first-page":"e21965","DOI":"10.1371\/journal.pone.0021965","article-title":"Solution structure of tensin2 SH2 domain and its phosphotyrosine-independent interaction with DLC-1","volume":"6","author":"Dai","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bpj.2022.05.030_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1083\/jcb.200608015","article-title":"The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1","volume":"176","author":"Liao","year":"2007","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1074\/mcp.M700312-MCP200","article-title":"Defining the specificity space of the human SRC homology 2 domain","volume":"7","author":"Huang","year":"2008","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bpj.2022.05.030_bib70","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1038\/s41598-020-70034-w","article-title":"The dynamics of free and phosphopeptide-bound Grb2-SH2 reveals two dynamically independent subdomains and an encounter complex with fuzzy interactions","volume":"10","author":"Sanches","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bpj.2022.05.030_bib71","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/pmic.201100599","article-title":"High-throughput analysis of peptide-binding modules","volume":"12","author":"Liu","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.bpj.2022.05.030_bib72","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.1021\/acs.jpcb.8b05982","article-title":"Calmodulin (CaM) activates PI3K\u03b1 by targeting the \u201csoft\u201d CaM-binding motifs in both the nSH2 and cSH2 domains of p85\u03b1","volume":"122","author":"Zhang","year":"2018","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.bpj.2022.05.030_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-2836(88)90103-9","article-title":"Analysis and prediction of the different types of beta-turn in proteins","volume":"203","author":"Wilmot","year":"1988","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib74","first-page":"2777","article-title":"Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps\/fes, GRB-2, HCP, SHC, Syk, and Vav","volume":"14","author":"Songyang","year":"1994","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bpj.2022.05.030_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10799893.2016.1155067","article-title":"Structural basis of focal adhesion targeting domain-mediated signaling in cardiac hypertrophy","volume":"37","author":"Mohanty","year":"2017","journal-title":"J.\u00a0Recept. Signal Transduct. Res."},{"key":"10.1016\/j.bpj.2022.05.030_bib76","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bpj.2022.05.030_bib77","doi-asserted-by":"crossref","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","article-title":"Conformational states dynamically populated by a kinase determine its function","volume":"370","author":"Xie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bpj.2022.05.030_bib78","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1039\/c3cs35449k","article-title":"Progress towards the development of SH2 domain inhibitors","volume":"42","author":"Kraskouskaya","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bpj.2022.05.030_bib79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1006\/jmbi.2001.5299","article-title":"Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor","volume":"315","author":"Nioche","year":"2002","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bpj.2022.05.030_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbapap.2004.10.005","article-title":"The SH2 domain: versatile signaling module and pharmaceutical target","volume":"1747","author":"Machida","year":"2005","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Biophysical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006349522004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006349522004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T17:01:31Z","timestamp":1757782891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006349522004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0006349522004234"],"URL":"https:\/\/doi.org\/10.1016\/j.bpj.2022.05.030","relation":{},"ISSN":["0006-3495"],"issn-type":[{"value":"0006-3495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Biophysical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpj.2022.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Biophysical Society.","name":"copyright","label":"Copyright"}]}}